17.06.2025, 12:11
Ozon Pharmaceuticals plans to launch an SPO at a price not exceeding 48 rubles per share.
Source: OREANDA-NEWS
OREANDA-NEWS PJSC Ozon Pharmaceuticals is launching a secondary public offering of shares (SPO) on the Moscow Stock Exchange, the company said in a statement.
The SPO price will be determined based on the results of the order book formation, but will not exceed 48 rubles per share. At the same time, it is also expected that it will not exceed the closing price of the main trading session on the Moscow Stock Exchange on June 19, the last day of the bid collection.
The selling shareholder is Ozon LLC, a subsidiary of the company, which received shares from Pavel Aleksenko, founder and chairman of the Board of Directors of Ozon Pharmaceuticals, on the basis of a securities loan agreement. It is assumed that Ozon Pharmaceuticals will then issue additional shares by open subscription at the SPO placement price. The funds raised by the selling shareholder will be directed to the company through the purchase of additional issue shares.
The SPO will offer from 55 million to 82 million shares, which corresponds to 5-7.5% of the number of outstanding shares of the company. As a result of the SPO, the free float may increase to 15.3%.
The collection of applications for participation in the SPO will last from 17 to 19 June inclusive, but may be completed ahead of schedule by decision of the selling shareholder.
"The increase in free-float is consistent with our intentions to expand the shareholder base, increase the trading liquidity of the shares and attract additional attention to the shares of new investor groups. This, in our opinion, will contribute to further growth in the capitalization of a dynamically developing business," Aleksenko said in a statement.
He also noted that the funds raised under the secondary offer will be fully transferred to the company (cash-in) and will be used to implement a strategy of sustainable and profitable growth. Following the results of all stages of the transaction, the number of shares owned by Aleksenko will not change.
Investors who purchase shares under the SPO will receive a preferential right to participate in the subsequent additional issue of the company at the same price as in the SPO, which will allow them to retain their ownership stake in the capital of PJSC Ozon Pharmaceuticals.
As reported, in October 2024, Ozon Pharmaceuticals conducted an IPO on the Moscow Stock Exchange in the amount of 3.45 billion rubles. The funds raised are aimed at implementing a growth strategy: expanding the range of generic and biosimilar drugs, as well as launching new production facilities.
The authorized capital of PJSC after the IPO consists of 1 billion 98 million 571.44 thousand ordinary shares with a nominal value of 0.02 rubles.
According to the company's report for 2024, Aleksenko owns 40.1% of the share capital of PJSC Ozon Pharmaceuticals, and Yuri and Vladimir Kornev own 14.5% and 10.9%, respectively. Ozone Pharmaceuticals' free-float is 10%.
Ozon Pharmaceuticals has been operating since 2001, with production facilities located in Zhigulevsk and the Tolyatti SEZ. In addition, the company's research laboratories are located in the Skolkovo biopharmaceutical cluster and in the city of Khimki.
The SPO price will be determined based on the results of the order book formation, but will not exceed 48 rubles per share. At the same time, it is also expected that it will not exceed the closing price of the main trading session on the Moscow Stock Exchange on June 19, the last day of the bid collection.
The selling shareholder is Ozon LLC, a subsidiary of the company, which received shares from Pavel Aleksenko, founder and chairman of the Board of Directors of Ozon Pharmaceuticals, on the basis of a securities loan agreement. It is assumed that Ozon Pharmaceuticals will then issue additional shares by open subscription at the SPO placement price. The funds raised by the selling shareholder will be directed to the company through the purchase of additional issue shares.
The SPO will offer from 55 million to 82 million shares, which corresponds to 5-7.5% of the number of outstanding shares of the company. As a result of the SPO, the free float may increase to 15.3%.
The collection of applications for participation in the SPO will last from 17 to 19 June inclusive, but may be completed ahead of schedule by decision of the selling shareholder.
"The increase in free-float is consistent with our intentions to expand the shareholder base, increase the trading liquidity of the shares and attract additional attention to the shares of new investor groups. This, in our opinion, will contribute to further growth in the capitalization of a dynamically developing business," Aleksenko said in a statement.
He also noted that the funds raised under the secondary offer will be fully transferred to the company (cash-in) and will be used to implement a strategy of sustainable and profitable growth. Following the results of all stages of the transaction, the number of shares owned by Aleksenko will not change.
Investors who purchase shares under the SPO will receive a preferential right to participate in the subsequent additional issue of the company at the same price as in the SPO, which will allow them to retain their ownership stake in the capital of PJSC Ozon Pharmaceuticals.
As reported, in October 2024, Ozon Pharmaceuticals conducted an IPO on the Moscow Stock Exchange in the amount of 3.45 billion rubles. The funds raised are aimed at implementing a growth strategy: expanding the range of generic and biosimilar drugs, as well as launching new production facilities.
The authorized capital of PJSC after the IPO consists of 1 billion 98 million 571.44 thousand ordinary shares with a nominal value of 0.02 rubles.
According to the company's report for 2024, Aleksenko owns 40.1% of the share capital of PJSC Ozon Pharmaceuticals, and Yuri and Vladimir Kornev own 14.5% and 10.9%, respectively. Ozone Pharmaceuticals' free-float is 10%.
Ozon Pharmaceuticals has been operating since 2001, with production facilities located in Zhigulevsk and the Tolyatti SEZ. In addition, the company's research laboratories are located in the Skolkovo biopharmaceutical cluster and in the city of Khimki.
Комментарии